Priority Health to cover FoundationOne genomic profiles

Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership

Richard Pazdur, founding director of FDA’s Oncology Center of Excellence and long-time FDA visionary, has accepted the top job at FDA’s Center for Drug Evaluation and Research following George F. Tidmarsh’s dramatic ouster from the position.

November 12, 2025

Podcast The Directors

The Directors: Ruben Mesa and Kunle Odunsi on how immigration and diversity accelerate discovery
“This has always made our environment stronger, not weaker.”

At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.

November 07, 2025

Vol.51 No.41

By Jacquelyn Cobb and Paul Goldberg

Regulatory News

CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”

November 07, 2025

Vol.51 No.41

By Claire Marie Porter and Paul Goldberg

Guest Editorial

How George Tidmarsh crossed the FDA-industry Rubicon

To say that it has been an eventful few months for George Tidmarsh would be a bit of an understatement.

November 07, 2025

Vol.51 No.41

By Mikkael A. Sekeres

Guest Editorial

How next generation sequencing is powering the shift to more accessible—and comprehensive—cancer care

Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more

November 07, 2025

Vol.51 No.41

By Kathy Davy

City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure

As we mark Lung Cancer Awareness Month, it is a time to acknowledge that screening and prevention are vital, and equally crucial is ensuring that patients have access to state-of-the-art care and research. Herein, I spotlight some of the transformative work underway at City of Hope.

November 07, 2025

Vol.51 No.41

By Ravi Salgia

Priority Health to cover FoundationOne genomic profiles

YOU MAY BE INTERESTED IN

Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership

The Directors: Ruben Mesa and Kunle Odunsi on how immigration and diversity accelerate discovery
“This has always made our environment stronger, not weaker.”

CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval

How George Tidmarsh crossed the FDA-industry Rubicon

How next generation sequencing is powering the shift to more accessible—and comprehensive—cancer care

City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure

Renew today!

Subscriber content

Never miss an issue!

Login

Priority Health to cover FoundationOne genomic profiles

YOU MAY BE INTERESTED IN

Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership

The Directors: Ruben Mesa and Kunle Odunsi on how immigration and diversity accelerate discovery“This has always made our environment stronger, not weaker.”

CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”Cancer advocates express concern about comments that signal trouble for accelerated approval

How George Tidmarsh crossed the FDA-industry Rubicon

How next generation sequencing is powering the shift to more accessible—and comprehensive—cancer care

City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure

Never miss an issue!

Login

The Directors: Ruben Mesa and Kunle Odunsi on how immigration and diversity accelerate discovery
“This has always made our environment stronger, not weaker.”

CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval